To further accelerate growth, Rarity Bioscience announces today a new strategic
investment from Belgium based Novalis Biotech. The investment is facilitated as an
oversubscription of the recent round closed in November 2022. Apart from previous
owner, that round also included Wallenberg Investments through Navigare Venture,
now bringing the total investment round to €3M.
Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies
that revolutionise healthcare. The fund’s core competence lies in digitalization in the life
sciences with a focus on “enabling technologies” within research and manufacturing
technologies, genomics, bioinformatics, diagnostics, and personalised medicine.
”Rarity Bioscience impressed us with an exceptional team and pedigree of
Wim Van Criekinge, Co-founder and Managing Director Novalis Biotech
the founders. We share the company’s vision of deploying the elegant
superRCA technology in emerging liquid biopsy applications across various
oncology indications and beyond. We believe the combination of the
technology’s unprecedented sensitivity and compatibility with widely
available instrument infrastructure and workflows, will position the
company to become a highly differentiated player in molecular diagnostics”
Read the article in full, in English, here
Read the article in full, in Swedish, here
About Rarity Bioscience AB
Rarity Bioscience was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology, based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology. Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. Enabling full potential of liquid biopsies and radically improving cancer diagnostics.
